Parkinson’s disease - Articles - Page 29

Hematologic

Blood cells can tell tales about risk of neurological and psychiatric disorders

Jan. 25, 2023

A genome-wide association study (GWAS) from The University of Queensland has linked blood cell traits (BCTs) and neurological and psychiatric disorders (NPDs), providing a tool to improve patient treatments or repurposing different drugs. The researchers also found a cause-effect relationship between Parkinson's and platelet distribution width. In their study, published Jan. 25, 2023, in Cell Genomics, the scientists observed the genetic overlap between common NPDs and 29 BCTs, including functional genes, regulatory elements and new genetic correlations linked to hematological data and for these diseases.

Elderly woman holding illustration of brain with missing puzzle piece

Neurology/Psychiatric

Tyrosine kinase inhibitor suppresses neurodegeneration in Parkinson's disease

Jan. 19, 2023

By Mar de Miguel

In animal models, the experimental compound IkT-148009, an inhibitor of Abelson’s tyrosine kinase (c-Abl), prevented the accumulation of the misfolded protein α-synuclein, which is associated with Parkinson’s disease (PD). Treatment with the inhibitor prevented neurodegeneration.

Ipsen to make next move after Irlab pops LID off mixed phase IIb data

Jan. 18, 2023

By Randy Osborne

Irlab Therapeutics AB’s phase IIb exploration of the dopamine D3-receptor with the Ipsen SA-partnered oral antagonist mesdopetam in Parkinson’s disease (PD) levodopa-induced dyskinesia (LID) fell short in terms of the primary endpoint, but the company is holding out hope. Mesdopetam missed the primary endpoint of change in daily hours of “on” time – periods of adequate PD control – without troublesome dyskinesia as shown in patient diaries, the company said.

Nervtex’s movement disorders diagnostic assessment software gets NMPA approval

Jan. 17, 2023

By Zhang Mengying

Nervtex Co. Ltd.’s diagnostic assessment software Modas for movement disorders such as Parkinson’s disease has been given NMPA approval in China. Using smart mobile devices, Modas can process video data collected from people with potential or existing movement disorders when they are in any specific motion state.

Neurology/Psychiatric

Irlab nominates dopamine D1 and D2 receptor agonist IRL-1117 as drug candidate for Parkinson's disease

Jan. 12, 2023

Irlab Therapeutics AB has nominated a drug...

Stalicla pulls in shelved mavoglurant, targeting cocaine abuse

Jan. 9, 2023

By Nuala Moran

A drug that Novartis AG discontinued in fragile X syndrome in 2014 after it failed in two phase II/III trials has been in-licensed by neuroscience specialist Stalicla SA, which plans to revive the prospects of the glutamate receptor antagonist by applying its precision medicine technology to identify likely responders.

Parkinson's disease illustration showing neurons containing alpha-synuclein

Neurology/Psychiatric

Golexanolone improves symptoms of Parkinson's disease in preclinical model

Jan. 4, 2023

Umecrine Cognition AB has announced results showing that its GABA-A receptor-modulating steroid antagonist golexanolone reversed fatigue, anxiety, depression, and some cognitive and motor alterations in a preclinical model of Parkinson's disease. Compared to a control-operated group, models with Parkinson's disease showed increased fatigue in the treadmill test and anxiety in the open field test.

Neurology/Psychiatric

SLS-004 increases recovery of TH+ dopaminergic neurons in animal model of Parkinson's disease

Dec. 16, 2022

Seelos Therapeutics Inc. has announced in vivo data demonstrating that a single dose of SLS-004 downregulated the production of α-synuclein in an established α-synuclein overexpressing animal model of Parkinson's disease.

Anavex’s phase IIb/III study in AD hits its primary endpoint

Dec. 2, 2022

By Lee Landenberger

Anavex Life Sciences Corp. posted positive top-line data from its phase IIb/III study of ANAVEX 2-73-AD-004 (blarcamesine) in treating mild cognitive impairment due to Alzheimer’s disease (AD) and mild AD. The oral small-molecule activator of the sigma-1 receptor (SIGMAR1) met the study’s primary endpoints and key secondary endpoint with statistically significant results.

Neurology/Psychiatric

Vigil Neuroscience presents new TREM2 agonists

Dec. 1, 2022

Vigil Neuroscience Inc. has synthesized triggering receptor expressed on myeloid cells 2 (TREM2) agonists reported to be useful for the treatment of frontotemporal dementia, multiple sclerosis, rheumatoid arthritis, stroke, prion infections, Parkinson's, Alzheimer's and Nasu-Hakola diseases.